Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2007
10/31/2007EP1420801B1 Use of fucans in the treatment of adhesions, arthritis and psoriasis
10/31/2007EP1259626B1 Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins and screening methods for modulators
10/31/2007EP1242426B1 Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides as hiv protease inhibitors
10/31/2007EP1192247B9 Sphingosine kinase enzyme
10/31/2007EP1140198B1 Use of hyaluronan for the manufacture of a medicament for the enhancement of the efficacy of cytotoxic drugs
10/31/2007EP1012320B1 Use of multivalent chimeric peptide-loaded, mhc/ig molecules to detect, activate or suppress antigen-specific t cell-dependent immune responses
10/31/2007DE60126947T2 Behandlung der glykogenspeicherkrankheit typ ii Treatment of glycogen storage disease type ii
10/31/2007DE102006019589A1 Inhibitoren des TASK-1 und Task-3 Ionenkanals Inhibitors of the TASK-1 and Task 3 ion channel
10/31/2007CN101062053A Reduced toxicity cisplatin formulations and methods for using the same
10/31/2007CN100345842C Dimeric compounds and their use as anti-viral agents
10/31/2007CN100345596C medicinal aerosol formulation
10/31/2007CN100345593C Remedy or preventive for kidney disease and method of diagnosing kidney disease
10/30/2007US7288631 G-coupled receptor showing selective affinity for ATP
10/30/2007US7288571 Thyroid receptor ligands and method II
10/30/2007US7288570 Stimulation of in vivo production of proteins
10/30/2007US7288537 Azetidine derivatives as CCR-3 receptor antagonists
10/30/2007US7288535 Methods and compositions for stimulating bone growth using nitric oxide releasing bisphosphonate conjugates
10/30/2007US7288534 Sphingomyelin enhancement of tumor therapy
10/30/2007US7288521 Growth factor therapy mobilization of stem cells into the peripheral blood
10/30/2007US7288517 Especially treating Alzheimer's disease with cetrorelix.
10/30/2007US7288390 Anti-dual integrin antibodies, compositions, methods and uses
10/30/2007US7288267 Bioadhesive nanoparticulate compositions having cationic surface stabilizers
10/30/2007US7288260 Using botulinun toxin to treat pain for sustained release
10/30/2007US7288245 Composition having immunoregulating activities
10/30/2007CA2451433C Oligopeptide transporter 1 inhibitor
10/30/2007CA2330424C Improved method for eradication of helicobacter pylori
10/30/2007CA2297083C Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections
10/30/2007CA2286552C Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine
10/30/2007CA2220012C Methods for modulating t cell survival by modulating bcl-xl protein level
10/25/2007WO2007120787A2 Methods of treating, diagnosing or detecting cancers associated with liv-1 overexpression
10/25/2007WO2007120702A2 Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, and combination therapy relating thereto
10/25/2007WO2007119623A1 Novel use of g-protein-conjugated receptor and ligand thereof
10/25/2007WO2007119515A1 Novel tumor antigen peptides
10/25/2007WO2007119214A2 Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
10/25/2007WO2007119006A1 New medicines for treatments against retroviruses
10/25/2007WO2007118996A2 Use of at least one cytosolic phospholipase a2 inhibitor as a medicine for symptomatic treatment of mucoviscidosis
10/25/2007WO2007118984A1 Use of (s)-roscovitine for manufacturing a medicine
10/25/2007WO2007118602A1 Compounds for treating pulmonary hypertension
10/25/2007WO2007118294A1 Homeopathic composition and kit therefore
10/25/2007WO2007089903A3 Cationic steroid microbial compositions for treating or preventing influenza infections
10/25/2007WO2007049043A3 Tnf alpha ngf molecular switch for determining cell fate
10/25/2007WO2007024589A3 Phagocyte enhancement therapy for atherosclerosis
10/25/2007WO2003011210A3 Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase
10/25/2007WO2002099074A3 Slc7s as modifiers of the p53 pathway and methods of use
10/25/2007WO2002017853A3 Hyaluronan-based antiadhesion compositions, their preparation and use
10/25/2007US20070249692 Inhibitors of crystallization in a solid dispersion
10/25/2007US20070249676 Cyanoguanidine prodrugs
10/25/2007US20070249655 4-Substituted-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones
10/25/2007US20070249638 Derivatives of triazoly-imidazopyridine and of the triazolypurines useful as ligands of the adenosine A2a receptor and their use as medicaments
10/25/2007US20070249630 Phenethanolamine derivatives for treatment of respiratory diseases
10/25/2007US20070249622 Nicotinic receptor agonists and analogues and derivatives thereof for the treatment of inflammatory diseases
10/25/2007US20070249600 Chemical compounds
10/25/2007US20070249586 Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity
10/25/2007US20070249541 Combined use of enzyme inhibitors and of pharmaceutical compositions thereof
10/25/2007US20070249523 Neurotherapeutic composition and method therefor
10/25/2007US20070249509 Neutralizes the adverse health effects of both chemical and biological compounds, especially chemical warfare (CW) and biological warfare (BW) agents
10/25/2007US20070249033 Methods of terminal sterilization of biological products
10/25/2007US20070248972 Page-4, an X-linked gage-like gene expressed in normal and neoplastic prostate, testis and uterus, and uses therefor
10/25/2007US20070248724 Method and device for sanitation using bacteriophages
10/25/2007US20070248692 Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
10/25/2007US20070248676 Use of nitric oxide adducts
10/25/2007US20070248620 Method of treating malignancies and viral infections and improving immune function with a dietary supplement
10/25/2007US20070248606 Treatment of Alzheimer's disease
10/25/2007US20070248584 Immunomodulating Compositions, Uses Therefore and Processes for Their Production
10/25/2007US20070248577 Methods and compositions for administering stem cells
10/25/2007US20070248573 Chimeric Bacteriophages, Chimeric Phage-Like Particles, and Chimeric Phage Ghost Particles, Methods for Their Production and Use
10/25/2007US20070248572 Method for treating diseases with omega interferon
10/25/2007CA2650126A1 Methods of treating, diagnosing or detecting cancer
10/25/2007CA2649710A1 Use of opioid antagonists to attenuate endothelial cell proliferation and migration
10/25/2007CA2648239A1 Use of at least one cytosolic phospholipase a2 inhibitor as a medicine for symptomatic treatment of mucoviscidosis
10/25/2007CA2647694A1 Use of (s)-roscovitine for manufacturing a medicine
10/25/2007CA2643807A1 Homeopathic composition and kit therefore
10/24/2007EP1847620A2 Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
10/24/2007EP1847274A1 Association of phenylbutyrate, ATRA and cytidine and its use in anti-tumour therapy
10/24/2007EP1847244A1 Metabolic syndrome-improving agent and medicine, supplement, functional food and food additive containing the same
10/24/2007EP1846550A2 Use of the mcm8 gene for the preparation of a pharmaceutical composition
10/24/2007EP1846105A2 Use of adrenergic alpha2b antagonists for the treatment of vasomotor symptoms
10/24/2007EP1846036A1 Reducing drug dependence or addiction
10/24/2007EP1846035A2 Combination therapy
10/24/2007EP1846005A2 Kits and improved compositions for treating lower urinary tract
10/24/2007EP1845976A2 Use of inhibitors of soluble epoxide hydrolase to synergize activity of cox and 5-lox inhibitors
10/24/2007EP1845969A2 Compositions and methods relating to mitochondrial hyperpolarization in neurological disease
10/24/2007EP1845964A1 Antimicrobial compositions comprising a natural agent selected from gallic acid, eucalyptol, naringin, a jasmonic acid compound and any combination thereof
10/24/2007EP1845953A1 Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
10/24/2007EP1845944A2 Pharmaceutical compositions
10/24/2007EP1658081B1 Immunosuppressive effects of pteridine derivatives
10/24/2007EP1575590B1 Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
10/24/2007EP1505980B1 Microbicidal pyrimidine or triazine for preventing sexual hiv transmission
10/24/2007EP1471899B1 Use of ambroxol in the treatment of chronic pain
10/24/2007EP1178983B1 Indole-type derivatives as inhibitors of p38 kinase
10/24/2007EP1163019B1 Medical devices and applications of polyhydroxyalkanoate polymers
10/24/2007EP1156797B1 Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
10/24/2007EP1121431B9 Non-endogenous, constitutively activated human g protein-coupled receptors
10/24/2007CN101060860A Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
10/24/2007CN101057973A Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof
10/24/2007CN101057836A Application of honokiol in preparing medicine for treating acute leukemia
10/24/2007CN100344970C Treatment and diagnosis of cancer
10/24/2007CN100344277C Nano-magnetic medicinal microglobule, its preparation method and application
10/23/2007US7285661 Starch derivatives, starch active substance conjugates, method for the production thereof and their use as medicaments
10/23/2007US7285654 Stimulus-inducible protein kinase complex and methods of use therefor
1 ... 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 ... 1151